Cargando…

Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization

Spinal cord injury (SCI) is a devastating injury that may result in permanent motor impairment. The active ingredients of medications are unable to reach the affected area due to the blood‒brain barrier. Elamipretide (SS-31) is a new and innovative aromatic cationic peptide. Because of its alternati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haojie, Chen, Yituo, Li, Feida, Wu, Chenyu, Cai, Wanta, Ye, Hantao, Su, Haohan, He, Mingjun, Yang, Liangliang, Wang, Xiangyang, Zhou, Kailiang, Ni, Wenfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825014/
https://www.ncbi.nlm.nih.gov/pubmed/36609266
http://dx.doi.org/10.1186/s12974-023-02690-4
_version_ 1784866549303083008
author Zhang, Haojie
Chen, Yituo
Li, Feida
Wu, Chenyu
Cai, Wanta
Ye, Hantao
Su, Haohan
He, Mingjun
Yang, Liangliang
Wang, Xiangyang
Zhou, Kailiang
Ni, Wenfei
author_facet Zhang, Haojie
Chen, Yituo
Li, Feida
Wu, Chenyu
Cai, Wanta
Ye, Hantao
Su, Haohan
He, Mingjun
Yang, Liangliang
Wang, Xiangyang
Zhou, Kailiang
Ni, Wenfei
author_sort Zhang, Haojie
collection PubMed
description Spinal cord injury (SCI) is a devastating injury that may result in permanent motor impairment. The active ingredients of medications are unable to reach the affected area due to the blood‒brain barrier. Elamipretide (SS-31) is a new and innovative aromatic cationic peptide. Because of its alternating aromatic and cationic groups, it freely crosses the blood‒brain barrier. It is also believed to decrease inflammation and protect against a variety of neurological illnesses. This study explored the therapeutic value of SS-31 in functional recovery after SCI and its possible underlying mechanism. A spinal cord contusion injury model as well as the Basso Mouse Scale, footprint assessment, and inclined plane test were employed to assess how well individuals could function following SCI. The area of glial scarring, the number of dendrites, and the number of synapses after SCI were confirmed by HE, Masson, MAP2, and Syn staining. Western blotting, immunofluorescence, and enzyme-linked immunosorbent assays were employed to examine the expression levels of pyroptosis-, autophagy-, lysosomal membrane permeabilization (LMP)- and MAPK signalling-related proteins. The outcomes showed that SS-31 inhibited pyroptosis, enhanced autophagy and attenuated LMP in SCI. Mechanistically, we applied AAV vectors to upregulate Pla2g4A in vivo and found that SS-31 enhanced autophagy and attenuated pyroptosis and LMP by inhibiting phosphorylation of cPLA2. Ultimately, we applied asiatic acid (a p38-MAPK agonist) to test whether SS-31 regulated cPLA2 partially through the MAPK-P38 signalling pathway. Our group is the first to suggest that SS-31 promotes functional recovery partially by inhibiting cPLA2-mediated autophagy impairment and preventing LMP and pyroptosis after SCI, which may have potential clinical application value. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-023-02690-4.
format Online
Article
Text
id pubmed-9825014
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98250142023-01-08 Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization Zhang, Haojie Chen, Yituo Li, Feida Wu, Chenyu Cai, Wanta Ye, Hantao Su, Haohan He, Mingjun Yang, Liangliang Wang, Xiangyang Zhou, Kailiang Ni, Wenfei J Neuroinflammation Research Spinal cord injury (SCI) is a devastating injury that may result in permanent motor impairment. The active ingredients of medications are unable to reach the affected area due to the blood‒brain barrier. Elamipretide (SS-31) is a new and innovative aromatic cationic peptide. Because of its alternating aromatic and cationic groups, it freely crosses the blood‒brain barrier. It is also believed to decrease inflammation and protect against a variety of neurological illnesses. This study explored the therapeutic value of SS-31 in functional recovery after SCI and its possible underlying mechanism. A spinal cord contusion injury model as well as the Basso Mouse Scale, footprint assessment, and inclined plane test were employed to assess how well individuals could function following SCI. The area of glial scarring, the number of dendrites, and the number of synapses after SCI were confirmed by HE, Masson, MAP2, and Syn staining. Western blotting, immunofluorescence, and enzyme-linked immunosorbent assays were employed to examine the expression levels of pyroptosis-, autophagy-, lysosomal membrane permeabilization (LMP)- and MAPK signalling-related proteins. The outcomes showed that SS-31 inhibited pyroptosis, enhanced autophagy and attenuated LMP in SCI. Mechanistically, we applied AAV vectors to upregulate Pla2g4A in vivo and found that SS-31 enhanced autophagy and attenuated pyroptosis and LMP by inhibiting phosphorylation of cPLA2. Ultimately, we applied asiatic acid (a p38-MAPK agonist) to test whether SS-31 regulated cPLA2 partially through the MAPK-P38 signalling pathway. Our group is the first to suggest that SS-31 promotes functional recovery partially by inhibiting cPLA2-mediated autophagy impairment and preventing LMP and pyroptosis after SCI, which may have potential clinical application value. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-023-02690-4. BioMed Central 2023-01-07 /pmc/articles/PMC9825014/ /pubmed/36609266 http://dx.doi.org/10.1186/s12974-023-02690-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Haojie
Chen, Yituo
Li, Feida
Wu, Chenyu
Cai, Wanta
Ye, Hantao
Su, Haohan
He, Mingjun
Yang, Liangliang
Wang, Xiangyang
Zhou, Kailiang
Ni, Wenfei
Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title_full Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title_fullStr Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title_full_unstemmed Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title_short Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization
title_sort elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cpla2-induced lysosomal membrane permeabilization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825014/
https://www.ncbi.nlm.nih.gov/pubmed/36609266
http://dx.doi.org/10.1186/s12974-023-02690-4
work_keys_str_mv AT zhanghaojie elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT chenyituo elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT lifeida elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT wuchenyu elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT caiwanta elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT yehantao elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT suhaohan elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT hemingjun elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT yangliangliang elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT wangxiangyang elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT zhoukailiang elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization
AT niwenfei elamipretidealleviatespyroptosisintraumaticallyinjuredspinalcordbyinhibitingcpla2inducedlysosomalmembranepermeabilization